Advances in the Research of a Key Molecule in Periostin

Dear Colleagues,

Periostin is highly expressed in chronic inflammatory diseases, including asthma, eosinophilic chronic sinusitis/chronic rhinosinusitis with nasal polyp, steroid-resistant atopic dermatitis, chemotherapy-resistant cancer, acute myocardial infarction, congestive heart failure, atherosclerosis, stroke, acute kidney injury, and others. Moreover, periostin plays important roles in the pathogenesis of these diseases. Recently, it has been reported that periostin is involved in type 2 immunity, and is a biomarker of type 2 immunity. Periostin is also a therapeutic target for these diseases, which is why periostin research is very important for intractable diseases.

On the other hand, the protein periostin has a structure composed of an amino-terminal EMI domain, a tandem repeat of 4 fas 1 domains, and a carboxyl-terminal domain including a heparin-binding site at its C-terminal end. Therefore, periostin is one of the fasciclin 1 family. It is becoming clear that both the N-terminal and C-terminal of periostin have important functions.

Dr. Yoshiaki Taniyama
Dr. Nobutaka Koibuchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• splicing variant
• cancer
• inflammatory disease
• bone and dental disease
• retinopathy